18-F-L 3,4-Dihydroxyphenylalanine PET/Computed Tomography in the Management of Congenital Hyperinsulinism.
PET Clin
; 15(3): 349-359, 2020 Jul.
Article
en En
| MEDLINE
| ID: mdl-32498990
ABSTRACT
Congenital hyperinsulinism (HI) is the most common cause of persistent hypoglycemia in neonates and infants. Several genetic mutations have been identified and are associated with 2 distinct histopathologic forms of disease diffuse and focal. Targeted clinical evaluation to distinguish medically treatable disease from disease requiring surgical management can prevent life-threatening complications. Detection and localization of a surgically curable focal lesion using PET imaging with 18-F-L 3,4-dihydroxyphenylalanine ([18F]-FDOPA) has become standard of care. This article provides guidelines for the selection of patients who can benefit from [18F]-FDOPA-PET/computed tomography and protocols and tips used to diagnose a focal lesion of HI.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Dihidroxifenilalanina
/
Hiperinsulinismo Congénito
/
Tomografía Computarizada por Tomografía de Emisión de Positrones
Tipo de estudio:
Guideline
Límite:
Humans
/
Infant
Idioma:
En
Revista:
PET Clin
Año:
2020
Tipo del documento:
Article